ABSORPTION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) FROM RAT NASAL-MUCOSA

被引:28
作者
MACHIDA, M
SANO, K
ARAKAWA, M
HAYASHI, M
AWAZU, S
机构
[1] TOKYO COLL PHARM, DEPT BIOPHARMACEUT, 1432-1 HORINOUCHI, HACHIOJI, TOKYO 19203, JAPAN
[2] CHUGAI PHARMACEUT CO LTD, DIV DEV & TECHNOL, FORMULAT TECHNOL LAB, TOSHIMA KU, TOKYO 171, JAPAN
关键词
GRANULOCYTE COLONY-STIMULATING FACTOR (RHG-CSF); RECOMBINANT HUMAN GRANULOCYTE-CSF; NASAL ABSORPTION IN RATS; BIOAVAILABILITY; LEUKOCYTE NUMBER;
D O I
10.1023/A:1018990318090
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nasal absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) was examined in the rat. The relative bioavailability of rhG-CSF for subcutaneous administration was approximately 2%, as evaluated from the immunologically active rhG-CSF concentration in rat plasma and the area under the curve (AUC) of the plasma rhG-CSF concentration versus time for 8 hr. Pharmacological availability relative to subcutaneous administration was determined from the increase in total blood leukocyte numbers. The pharmacological availability was 5-10%, determined from the AUC for the increased ratio of total leukocyte numbers versus time for 48 hr; it was slightly dependent on the pH and the osmotic pressure of the dosing solution. Accordingly, the plasma concentration of rhG-CSF did not always reflect its pharmacological effects. Relative bioavailability and pharmacological availability were increased about 23 times and 3 times, respectively, by polyoxyethylene 9-lauryl ether (Laureth-9), but no increase in availability occurred with sodium glycocholate. The increase in total leukocyte numbers was maintained during multiple rhG-CSF dosing, and the addition of Laureth-9 further increased the pharmacological effects of this agent. This study indicates that nasal administration of rhG-CSF is an effective parenteral administration route.
引用
收藏
页码:1372 / 1377
页数:6
相关论文
共 13 条
[1]  
CHIEN YW, 1987, CRC CR REV THER DRUG, V4, P67
[2]   ABSORPTION OF RECOMBINANT METHIONYL-HUMAN GROWTH-HORMONE (MET-HGH) FROM RAT NASAL-MUCOSA [J].
DAUGHERTY, AL ;
LIGGITT, HD ;
MCCABE, JG ;
MOORE, JA ;
PATTON, JS .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 45 (03) :197-206
[3]   THE MOLECULAR-WEIGHT DEPENDENCE OF NASAL ABSORPTION - THE EFFECT OF ABSORPTION ENHANCERS [J].
DONOVAN, MD ;
FLYNN, GL ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1990, 7 (08) :808-815
[4]  
HIRAI S, 1981, INT J PHARM, V9, P165
[5]  
HIRAI S, 1981, INT J PHARM, V7, P317
[6]   PROTECTIVE ACTIVITY OF RECOMBINANT CYTOKINES AGAINST SENDAI VIRUS AND HERPES-SIMPLEX VIRUS (HSV) INFECTIONS IN MICE [J].
IIDA, J ;
SAIKI, I ;
ISHIHARA, C ;
AZUMA, I .
VACCINE, 1989, 7 (03) :229-233
[7]  
Kamachi S, 1991, KISO TO RINSHO, V25, P311
[8]   ANALYSIS OF STRUCTURAL REQUIREMENTS FOR THE ABSORPTION OF DRUGS AND MACROMOLECULES FROM THE NASAL CAVITY [J].
MCMARTIN, C ;
HUTCHINSON, LEF ;
HYDE, R ;
PETERS, GE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (07) :535-540
[9]   QUANTITATIVE ENZYME-IMMUNOASSAY FOR HUMAN GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) [J].
MOTOJIMA, H ;
KOBAYASHI, T ;
SHIMANE, M ;
KAMACHI, S ;
FUKUSHIMA, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 118 (02) :187-192
[10]   THE CHROMOSOMAL GENE STRUCTURE AND 2 MESSENGER-RNAS FOR HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR [J].
NAGATA, S ;
TSUCHIYA, M ;
ASANO, S ;
YAMAMOTO, O ;
HIRATA, Y ;
KUBOTA, N ;
OHEDA, M ;
NOMURA, H ;
YAMAZAKI, T .
EMBO JOURNAL, 1986, 5 (03) :575-581